~~<i id='6A27164A1A'><strike id='6A27164A1A'><tt id='6A27164A1A'><pre id='6A27164A1A'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：entertainment 2025-10-02 15:41:19 Page View：215

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Average age of first period drops to 11.9 years, study shows
Next article： Medicare proposal to cover medical devices draws a mixed reaction

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Hilary may become 1st tropical storm to make landfall in California in 84 years

1:28AsatelliteimageshowsTropicalStormHilarynearthePacificcoastofMexico,Aug.17,2023.NOAAHurricaneHila

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Eye stem cell transplant could help restore vision in injured people

UlaJurkunas,associatedirectorofthecorneaserviceatMassEyeandEar,performsthefirstCALECsurgery.Courtesy